Project information
From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
- Project Identification
- MSM0021622434
- Project Period
- 1/2007 - 12/2013
- Investor / Pogramme / Project type
-
Ministry of Education, Youth and Sports of the CR
- Research Intents
- MU Faculty or unit
- Faculty of Medicine
- Keywords
- multiple myeloma; proteomics; genomics
Monoclonal gammapathies and multiple myeloma in particular are among the most common and debilitating malignancies in the elderly population. In the last decade, there have been dramatic developments in basic and applied research in the field. New treatments have become available and treatment standards have changed. Treatment results have substantially improved and the probability of 10-year survival increased from 5% to 20% in the last decade. However, the disease is still incurable. The treatment strategy today includes potentially 3-5 regimens administered over a period of 10 to 15 years. There is increased tendency to apply treatment specifically tailored for a subgroup of patients with a well-defined risk and response rate.
Publications
Total number of publications: 314
2011
-
Monitoring of minimal residual disease in multiple myeloma patients: Development and standardization of method.
Year: 2011, type: Conference abstract
-
Monoclonal Gammopathy of Undeterminated Significance: Introduction and Current Clinical Issues
Klinická onkologie, year: 2011, volume: 24, edition: Suppl.
-
Multiple Myeloma
Klinická onkologie, year: 2011, volume: 24, edition: Suppl.
-
Multiple myeloma associated IgA pemphigus: complete remission after therapy with bortezomib, cyclophosphamide and dexamethasone regimen
Year: 2011, type: Conference abstract
-
Multiple Myeloma Associated IgA Pemphigus: Treatment With Bortezomib- and Lenalidomide-Based Regimen
Clinical Lymphoma, Myeloma & Leukemia, year: 2011, volume: 11, edition: 6, DOI
-
Myeloid-derived suppressor cells are elevated in MGUS and MM patients
Year: 2011, type: Conference abstract
-
Nestin - prognostický a myelom-specifický marker pro mnohočetný myelom?
Year: 2011, type: Conference abstract
-
Neural stem cell marker nestin as a potential unfavorable factor for multiple myeloma
Year: 2011, type: Conference abstract
-
Neural stem cell marker nestin as a specific marker for plasma cells of multiple myeloma patients.
Year: 2011, type: Conference abstract
-
Obecná onkologie
Year: 2011, edition: První vydání, number of pages: 394 s.